In vitro antimicrobial activity of 7432-S and its therapeutic efficacy in chronic respiratory tract infections

Akira Watanabe, Kotaro Oizumi, Seiichi Aonuma, Reiko Ono, Yoshihiro Honda, Yutaka Tokue, Kyoskil Konno

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)


    We studied the in vitro antimicrobial activity of 7432-S, a new cephem antibiotic for oral use, and evaluated its therapeutic efficacy in chronic respiratory tract infections. The minimum inhibitory concentrations (MICs) of 7432-S, cefaclor (CCL), cefixime (CFIX) and amoxicillin (AMPC) against 20 strains each of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa were determinedby a microbroth dilution method using the Dynatech MIC-2000 system. The results showed that 7432-S was less active than other antibiotics against S. aureus, was as active as cefixime and more active than cefaclor and amoxicillin against E. coli, K. pneumoniae, E. cloacae and S. marcescens. 7432-S was not as potent as the other agents against P. aeruginosa. A daily dose of 300 mg of 7432-S was given orally to 11 patients: 2 with infected bronchiectasis, 6 with chronic bronchitis, 1 with diffuse panbronchiolitis and 1 each with infection superimposed on pulmonary fibrosis and lung cancer. The clinical effect was good in 7, fair in 1 and poor in 3. Eleven strains were identified as causative organisms. Eight of these were eradicated by 7432-S. Eosinophilia was observed in 2 patients. A transient elevation of s-GOT and s-GPT values was observed in one patient. The adverse reactions disappeared after completion of the therapy. From the above results, we concluded that 7432-S is a most useful first choice antibiotic for oral use in chronic respiratory tract infections.

    Original languageEnglish
    Pages (from-to)148-157
    Number of pages10
    Publication statusPublished - 1989 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'In vitro antimicrobial activity of 7432-S and its therapeutic efficacy in chronic respiratory tract infections'. Together they form a unique fingerprint.

    Cite this